Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin vs Standard Therapy in Community-Acquired Pneumonia
NCT00717561Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2008
- Primary completion
- May 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of moxifloxacin in community acquired pneumonia (CAP) (2 arms), sponsored by Bayer. Primary endpoint: Clinical response 20 days after completion of study treatment (Test-of-Cure visit). Started Feb 2008; status: completed.
02
Drugs
moxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT00717561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00717561.